Geron Corporation of Menlo Park, California, has announced that its application to test an embryonic stem cell therapy for spinal cord injury in humans has been approved by the US Food and Drug Administration. It is the first regulatory approval of a human trial involving embryonic stem cells, which have the ability to differentiate into any of the more than 200 specialised cells in the human body.
